SCHEMBL23354068

SCHEMBL23354068

Cc1c(C2(CNC(=O)c3ccccc3-c3ccc(C(F)(F)F)cc3)NC(=O)NC2=O)cnn1CC(F)(F)F

nearest known ligand 0.81

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ADAMTS7 Q9UKP4 20/20 0.81
ADAM10 O14672 1/20 0.48
ADAMTS4 O75173 1/20 0.48
MMP12 P39900 1/20 0.48
MMP15 P51511 1/20 0.48
ADAMTS12 P58397 1/20 0.48
ADAM8 P78325 1/20 0.48
ADAM17 P78536 1/20 0.48
ADAMTS5 Q9UNA0 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31676831 1.00 ADAMTS7 (0.81) ADAMTS7ADAM10ADAMTS4MMP12MMP15
SCHEMBL29978951 0.89 ADAMTS7 (1.00) ADAMTS7ADAM10ADAMTS4MMP12MMP15
SCHEMBL23353980 0.89 ADAMTS7 (1.00) ADAMTS7ADAM10ADAMTS4MMP12MMP15
SCHEMBL29979648 0.85 ADAMTS7 (1.00) ADAMTS7ADAM10ADAMTS4MMP12MMP15
SCHEMBL23354326 0.85 ADAMTS7 (1.00) ADAMTS7ADAM10ADAMTS4MMP12MMP15
SCHEMBL23354051 0.82 ADAMTS7 (0.74) ADAMTS7ADAM10ADAMTS4MMP12MMP15
SCHEMBL31676862 0.82 ADAMTS7 (0.74) ADAMTS7ADAM10ADAMTS4MMP12MMP15
SCHEMBL23354022 0.82 ADAMTS7 (0.80) ADAMTS7ADAM10ADAMTS4MMP12MMP15
SCHEMBL29979833 0.82 ADAMTS7 (0.80) ADAMTS7ADAM10ADAMTS4MMP12MMP15
SCHEMBL23354285 0.81 ADAMTS7 (0.73) ADAMTS7ADAM10ADAMTS4MMP12MMP15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4058448-B1 HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER AG (DE) 2024-05-29 EP disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-4058448-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2022-09-21 EP disclosed
WO-2021094436-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2021-05-20 WO disclosed
EP-3822268-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2021-05-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAM17 ADAMTS7 1/4885ADAM10 52/4885ADAMTS4 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.